CardioNova Overview

  • Founded
  • 2011
  • Status
  • Out of Business
  • Employees
  • 1
  • Latest Deal Type
  • Out of Business

CardioNova General Information


Provider of drugs intended to treat cardiovascular disease. The company's biotechnology drugs include AHRO-001 is aimed at treating dyslipidemia and preventing atherosclerosis, enabling clients to get rapid and cost-effective achievement of clinical objectives.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 12/19, building 1, Verkhnyaya
  • Radishchevskaya street
  • Moscow, 119180
  • Russia
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CardioNova Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Dec-2016 00000 Completed Out of Business
4. Early Stage VC 00000 Completed Generating Revenue
3. Accelerator/Incubator 21-Dec-2011 00000 Completed Generating Revenue
2. Seed Round 01-Jan-2011 $900K $900K Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view CardioNova’s complete valuation and funding history, request access »

CardioNova Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial